Neurocrine Biosciences, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kyle W. Gano
- Full Time Employees
- 2,000
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 6027 Edgewood Bend Court San Diego CA United States 92130
- IPO Date
- May 23, 1996
- CIK
- 0000914475
- Website
- neurocrine.com
- Similar Companies
- Business
- Neurocrine Biosciences, Inc. (NBIX) is a neuroscience-focused biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for neurological, neuroendocrine and neuropsychiatric disorders. Founded in 1992 and headquartered in San Diego, California, the company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved for tardive dyskinesia in adults and chorea associated with Huntington's disease; ONGENTYS (opicapone), a catechol-O-methyltransferase inhibitor licensed for Parkinson's disease; and partnered products including ORILISSA (elagolix) and ORIAHNN for endometriosis and uterine fibroids. Its pipeline features NBI-1117568, a muscarinic receptor agonist in Phase II for schizophrenia; osavampator (formerly NBI-1065845), an AMPA positive allosteric modulator for major depressive disorder; and preclinical NLRP3 inhibitors for neuroinflammation and immunology; the company operates primarily in the United States with global partnerships. Recent developments include a January 2025 amendment to its collaboration with Takeda, granting Neurocrine exclusive worldwide rights (except Japan) to osavampator following positive End-of-Phase 2 FDA feedback; a November 2025 global licensing agreement with Pharmaron (up to $881.5 million) and collaboration with TransThera Sciences for NLRP3 inhibitors outside Greater China; and strong third-quarter 2025 financial results with INGREZZA net sales of $687 million.
Company News
Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth Stock
Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
Where Will Neurocrine Biosciences Be in 5 Years?
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term
Head-To-Head Contrast: Neurocrine Biosciences (NASDAQ:NBIX) vs. Amneal Pharmaceuticals (NASDAQ:AMRX)
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
4 CNS Drug Stocks Worth Watching This World Mental Health Day
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Borg Warner, Boyd Gaming, JetBlue, Lattice Semiconductor, Lockheed Martin, Nike, Northrop Grumman, Procter & Gamble, SPX Technologies, and More
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D.
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
Integrated Wealth Concepts LLC Sells 5,703 Shares of Neurocrine Biosciences, Inc. $NBIX
Corient Private Wealth LP Buys 9,645 Shares of Neurocrine Biosciences, Inc. $NBIX